Meeting NewsVideo

VIDEO: Top takeaways from ESC Congress with Dipti Itchhaporia, MD

PARIS — In this video exclusive, Dipti Itchhaporia, MD, FACC, with Hoag Heart and Vascular Institute in Newport Beach and University of California, Irvine, and vice president-elect of the American College of Cardiology, provides highlights from the 2019 European Society of Cardiology Congress.

Topping her list are DAPA-HF, which studied the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) in patients with HF, with and without diabetes; COMPLETE, which compared complete revascularization and culprit lesion-only PCI in patients with STEMI and multivessel CAD; and ISAR-REACT 5, which evaluated outcomes with prasugrel (Effient, Daiichi Sankyo/Eli Lilly) vs. ticagrelor (Brilinta, AstraZeneca) in patients with acute coronary syndromes.

Itchhaporia, a Cardiology Today Editorial Board Member, provides insight on these important trials.

Watch the video for more.

PARIS — In this video exclusive, Dipti Itchhaporia, MD, FACC, with Hoag Heart and Vascular Institute in Newport Beach and University of California, Irvine, and vice president-elect of the American College of Cardiology, provides highlights from the 2019 European Society of Cardiology Congress.

Topping her list are DAPA-HF, which studied the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) in patients with HF, with and without diabetes; COMPLETE, which compared complete revascularization and culprit lesion-only PCI in patients with STEMI and multivessel CAD; and ISAR-REACT 5, which evaluated outcomes with prasugrel (Effient, Daiichi Sankyo/Eli Lilly) vs. ticagrelor (Brilinta, AstraZeneca) in patients with acute coronary syndromes.

Itchhaporia, a Cardiology Today Editorial Board Member, provides insight on these important trials.

Watch the video for more.

    See more from European Society of Cardiology Congress